Member Info for OAPK20

Perhaps you should’ve got in before the SP went above 2p. Do you hold shares here?

Directors have been in closed period so unable to buy in open market. See recent interview with CEO. DYOR.

3023 is a long way off. I’m hoping to have taken profit by then ;-)

All the late comers spewing “Do we need to raise” “Is there a placing”

Where they been ? It’s comical.

First attempt at 4.2p. Once the profit takers finish and 4.2p goes.............

None taking I got in here January. Very happy. Reckoned it was around 11p valuation on listing day after placing.
Either or it’s going higher than that on validation and commercialisation

Only 22,000,000 new ordinary shares at 10p per share were issued following admission of 253,447,788 on first day of dealings.

DYOR. Too many trying to make out it was an IPO with full admission of shares at 10p.

Highlights

-- In 2020 the Company was focussed on undertaking a reverse takeover which completed post period end.

-- Completion of the acquisition of Cizzle Biotechnology Limited on 14 May 2021. Cizzle Biotechnology is developing a blood test for the early detection of lung cancer by detecting a stable plasma biomarker known as CIZ1B. The biomarker is highly correlated with early-stage lung cancer.

-- Placing to raise gross proceeds of GBP2.2 million in conjunction with the admission to trading of the Company's shares on the Main Market of the London Stock Exchange on 14 May 2021.

Alert. Good luck see you at 50

Not my data. It’s in CIZ RNS. 10% for CIZ is £300,000,000 per annum. Unless my arithmetic is incorrect.

RNS Number : 5310A

Cizzle Biotechnology Holdings PLC

03 February 2022

"This agreement represents a significant opportunity to bring early and cost-effective cancer detection to the people of China. It is estimated that about 95.8 million people in China have a high risk of lung cancer and if screening was performed every three years, then more than 30 million tests per year would be required. At a target price of about GBP100 per test, the total available market for tests based on the CIZ1B biomarker would be GBP3 billion. (Frost & Sullivan estimates the market size in China is US$5.7 billion). We have already secured strong interest from our nationwide network of national clinical centers and key opinion leaders because of the promising results using the CIZ1B biomarker for lung cancer early detection in the UK and one our first tasks is to commence pilot studies at the Cancer Hospital, Chinese Academy of Medical Sciences, National Cancer Centre, and Beijing Cancer Hospital, affiliated with Peking University."

CorePath in US stated in November during CEO visit they were on track for validation and commercialisation during 2023.

This needs news to support its rise before the Hopeium Bubble bursts.

US China or perhaps new licence partner to target NHS.

RNS

2 March 2023

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

Biofungicide PHC279 Approved by US EPA

Plant Health Care(R) (AIM: PHC.L), a leading provider of novel patent-protected biological crop protection products to global agriculture markets, is pleased to announce US Environmental Protection Agency commercial approval of its novel peptide fungicide, coded as PHC279.

Wilbur-Ellis(R) Agribusiness, one of the largest U.S. retailers of agricultural products, is expected to commence sales of PHC279 within key US markets under the brand Obrona in 2023.

No turnover for 30,000,000 tests a year at £100 is £3,000,000,000 so 10% is £300,000,000

China = 30,000,000 tests per year at £100 per test. 10% to CIZ is £300,000,000 from China alone.

DYOR.

CorePath tweet 9/11/22

Thank you Dr. Allan Syms Exec. Chairman of @CizzlePlc for visiting CorePath. Excited to continue partnership to develop & offer a proprietary #earlystage #lungcancer test throughout the USA.

On track to validating/commercializing the test in 2023.

#cancer #CIZ #CaringforLives

Pumped dumped and shorted. They’ll be deleting the tweets

Take it a short was opened before the tweet

More profit taking. Hope its not a pre result dump

Just another 3502206 shares - TR1 - up tp 9.03%

follow the money.

Cont…
Over two years of trials the integrated biological programme has been shown to reduce the amount of synthetic fungicides needed to maintain fruit quality by 58%

The most recent research, carried out under Agrii’s Green Horizons sustainable food production project has taken this further. In a recent trial, strawberries treated with a biological input programme including ProAct® had more than 20% less rotted fruit than those berries treated with a traditional standard programme programme of boscalid, pyraclostrobin, cyprodinil, fludioxonil and fenhexamide 2. Building on this finding, Agrii have developed an integrated biological programme for strawberries combining commercial biofungicides and ProAct®. Over two years of trials the integrated biological programme has been shown to reduce the amount of synthetic fungicides needed to maintain fruit quality by 58% 3. This is a significant reduction for a crop which may typically receive upwards of 12 fungicide applications.

With the first harpin-derived PREtec peptides now reaching major global markets this is just the beginning of Plant Health Care's journey.